Fenoldopam and N-acetylcysteine for the Prevention of Radiographic Contrast Material-Induced Nephropathy: A Review

Pharmacotherapy

Volumn 23, Issue 12 I, 2003, Pages 1617-1626

  Walker, Paul D ^a,b   Brokering, Kristi L ^c   Theobald, John C ^d  

^a AUBURN UNIVERSITY   (United States)

^b UNIVERSITY OF ALABAMA   (United States)

^c ST LOUIS COLLEGE OF PHARMACY   (United States)

^d St Elizabeth's Hospital   (United States)

Author keywords

Fenoldopam; N acetylcysteine; Nephropathy; Radiographic contrast

Indexed keywords

ACETYLCYSTEINE; AMINOPHYLLINE; ATRIAL NATRIURETIC FACTOR; CALCIUM CHANNEL BLOCKING AGENT; CONTRAST MEDIUM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOPAMINE; FENOLDOPAM MESILATE; FUROSEMIDE; MANNITOL; PROSTAGLANDIN DERIVATIVE; SODIUM CHLORIDE; THEOPHYLLINE;

CLINICAL TRIAL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REGIMEN; DRUG EFFICACY; HUMAN; HYDRATION; KIDNEY DISEASE; KIDNEY FAILURE; PATHOPHYSIOLOGY; PATIENT CARE; PROPHYLAXIS; PROSPECTIVE STUDY; RADIOGRAPHY; RETROSPECTIVE STUDY; REVIEW; STANDARD;

ACETYLCYSTEINE; CONTRAST MEDIA; DOPAMINE AGONISTS; FENOLDOPAM; FREE RADICAL SCAVENGERS; HUMANS; ISCHEMIA; KIDNEY; KIDNEY DISEASES; RANDOMIZED CONTROLLED TRIALS;

EID: 0344442421     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.23.15.1617.31958     Document Type: Review

References (26)

1. Solomon R. Radiocontrast-induced nephropathy. Semin Nephrol 1998;18:551-7.
2. Murphy SW, Barrett BJ, Parfrey PS. Contrast nephropathy. J Am Soc Nephrol 2000;11:177-82.
3. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality: a cohort analysis. JAMA 1996;275:1489-94.
4. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-induced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-4.
5. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcysteine to prevent angiography-related renal tissue injury (the APART trial). Am J Cardiol 2002;89:356-8.
6. Briguouri C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol 2002;40:298-303.
7. Shyu KG, Cheng JJ, Kuan P. Acetylcysteine protects against acute renal damage in patients with abnormal renal function undergoing a coronary procedure. J Am Coll Cardiol 2002;40:1383-8.
8. Durham JD, Caputo C, Dokko J, et al. A randomized controlled trial of N-acetylcysteine to prevent contrast nephropathy in cardiac angiography. Kidney Int 2002;62:2202-7.
9. Kay J, Chow WH, Chan TM, et al. Acetylcysteine for prevention of acute deterioration of renal function following elective coronary angiography and intervention. JAMA 2003;289:553-8.
10. Allaqaband S, Tumuluri R, Malik AM, et al. Prospective randomized study of N-acetylcysteine, fenoldopam, and saline for prevention of radiocontrast-induced nephropathy. Catheter Cardiovasc Interv 2002;57:279-83.
11. Tumlin JA, Wang A, Murray PT, Mathur VS. Fenoldopam mesylate blocks reductions in renal plasma flow after radiocontrast dye infusion: a pilot trial in the prevention of contrast nephropathy. Am Heart J 2002;143:894-903.
12. Kini AS, Mitre CA, Kim M, Kamran M, Reich D, Sharma SK. A protocol for prevention of radiographic contrast nephropathy during percutaneous coronary intervention: effect of selective dopamine receptor agonist fenoldopam. Catheter Cardiovasc Interv 2002;55:169-73.
13. Madyoon H, Croushore L, Weaver D, Mathur V. Use of fenoldopam to prevent radiocontrast nephropathy in high-risk patients. Catheter Cardiovasc Interv 2001;53:341-5.
14. Kini AS, Mitre CA, Kamran M, et al. Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam. Am J Cardiol 2002;89:999-1002.
15. Chamsuddin AA, Kowalik KJ, Bjarnason H, et al. Using a dopamine type 1A receptor agonist in high-risk patients to ameliorate contrast-associated nephropathy Am J Roentgenol 2002;179:591-6.
16. Gerlach AT, Pickworth KK. Contrast medium-induced nephrotoxicity: pathophysiology and prevention. Pharmacotherapy 2000;20:540-8.
17. Quader MA, Sawmiller C, Sumpio BA. Contrast-induced nephropathy: review of incidence and pathophysiology. Ann Vasc Surg 1998;12:612-20.
18. Tublin ME, Murphy ME, Tessler FN. Current concepts in contrast media-induced nephropathy Am J Roentgenol 1998;171:933-9.
19. Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC Jr. Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. Am J Physiol 1990;258:F115-20.
20. Brezis M, Rosen S. Hypoxia of the renal medulla: its implications for disease. N Engl J Med 1995;332:647-55.
21. Heyman SN, Reichman J, Brezis M. Pathophysiology of radiocontrast nephropathy: a role for medullary hypoxia. Invest Radiol 1999;34:685-91.
22. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of saline, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;331:1416-20.
23. Adamian MG, Moussa I, Mehran R, et al. The role of Mucomyst administration prior to percutaneous interventions on renal function in patients with chronic kidney disease [abstr]. J Am Coll Cardiol 2002;39(suppl A):1A.
24. Mouhayar EN, Tadros G, Akinwande AAO, Campbell B, Blankenship JC, Iliadis EA. Prevention of contrast-induced renal dysfunction with acetylcysteine in patients undergoing coronary angiography [abstr]. J Am Coll Cardiol 2002;39(suppl A):1A.
25. Brophy DF. Role of N-acetylcysteine in the prevention of radiocontrast-induced nephropathy. Ann. Pharmacother 2002;36:1466-70.
26. Chu VL, Cheng JW. Fenoldopam in the prevention of contrast media-induced acute renal failure. Ann Pharmacother 2001;35:1278-82.